Sequence Optimization that Overcomes Prime Editing Efficiency Limits: epegRNA Design Innovation for DMD Gene Correction
##1. Safety Dilemma in DMD Gene Therapy and the Rise of Prime Editing Duchenne muscular dystrophy (DMD) is a lethal disease caused by mutations in the dystrophin gene. Conventional CRISPR‑Cas9 technology induces double‑strand DNA breaks (DSBs), carrying a high risk of unintended insertions/deletions (indels) or large‑scale genomic damage. Prime editing emerged as an alternative that can precisely correct target nucleotides without generating DSBs, garnering considerable interest; however, its low editing efficiency in hard‑to‑edit cells such as muscle cells has been the principal barrier to commercialization.
##2. The 5'-TTCT-3' Motif: An Invisible Barrier to epegRNA Performance The research team identified that a specific sequence dramatically reduces efficiency during the design of epegRNA (enhanced pegRNA), a core component of prime editing. Their investigation revealed that a 5'-TTCT-3' motif embedded in the RNA sequence acts as a decisive inhibitor of the prime editing system, either causing premature termination of RNA polymerase III (Pol III) transcription or compromising RNA structural stability. Consequently, the intracellular concentration of functional editing tools in muscle cells fails to reach effective levels.
##3. Silent Substitution: Dramatic Efficiency Gains through Sequence Optimization The team employed a silent substitution strategy—altering only the nucleotide sequence while preserving the encoded amino acid—to eliminate the 5'-TTCT-3' motif from epegRNA. This simple yet precise optimization increased editing efficiency by severalfold. In mouse muscle progenitor (C2C12) cells targeting the mdx-4cv and mdx-5cv mutations, the approach achieved remarkable correction rates of 20% with an NGG PAM and 21% with an NGAG PAM. These figures indicate that prime editing has reached efficacy levels suitable for therapeutic application.
##4. Why it Matters: Establishing Universal Design Guidelines and Accelerating Precise Gene Editing The critical importance of this work lies in its provision of a universal design rule applicable to all prime editing projects, extending beyond the specific case of DMD. By elucidating that certain motifs limit efficiency, researchers now possess clear guidance for designing high‑efficiency pegRNAs without trial‑and‑error. This advancement will dramatically accelerate the development of prime‑editing therapeutics for muscular disorders and a broad spectrum of genetic diseases, representing a pivotal shift that elevates precise gene correction from the laboratory to clinical practice.
Duchenne muscular dystrophy (DMD) is a fatal X-linked neuromuscular disorder caused by mutations in the dystrophin gene. Prime editing is a versatile genome editing technology capable of introducing precise nucleotide changes without generating double-strand DNA breaks, making it a promising approach for correcting pathogenic point mutations. In this study, we applied prime editing to modify mdx-4cv and mdx-5cv mutation-equivalent sites in mouse C2C12 myoblasts in vitro. Initial editing efficiencies were unexpectedly low and were associated with the presence of a 5'-TTCT-3' motif within engineered prime editing guide RNAs (epegRNAs). epegRNA designs containing this motif exhibited reduced prime editing efficiency, whereas silent substitution eliminating the motif significantly improved editing outcomes, indicating that specific sequence features within epegRNAs can influence editing performance. Rational redesign of epegRNAs to remove this motif substantially enhanced editing efficiency, achieving up to 20% modification at the 4cv target site using an NGG PAM and 21% editing at the 5cv locus using an NGAG PAM. These findings highlight an important sequence-dependent constraint in epegRNA design and provide practical guidance for optimizing prime editing strategies targeting
This dataset elucidates the mechanism of sequence‑dependent efficiency loss in prime editing and provides a concrete solution to overcome it. Notably, efficiencies exceeding 20% constitute a clinically relevant threshold capable of producing tangible improvements in muscle function, and the identified ‘Negative Motif’ serves as a unique training source for future AI‑driven pegRNA design algorithms.